The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

M. Solèr, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, G. Della Cioppa

Research output: Contribution to journalArticle

687 Scopus citations

Abstract

The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p

Original languageEnglish (US)
Pages (from-to)254-261
Number of pages8
JournalEuropean Respiratory Journal
Volume18
Issue number2
DOIs
StatePublished - Sep 3 2001

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics'. Together they form a unique fingerprint.

  • Cite this

    Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal, 18(2), 254-261. https://doi.org/10.1183/09031936.01.00092101